Weitere Formate
Autorenfreundlich Bücher kaufen?!
Beschreibung
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs.
Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
Details
| Verlag | Springer Paris |
| Ersterscheinung | 23. August 2016 |
| Maße | 23.5 cm x 15.5 cm |
| Gewicht | 470 Gramm |
| Format | Softcover |
| ISBN-13 | 9782817805573 |
| Auflage | Softcover reprint of the original 1st ed. 2016 |
| Seiten | 300 |
Schlagwörter
Herstellerinformationen
Bekannt durch
